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ORIGINAL RESEARCH
Cysteine- Rich Angiogenic Inducer 61 
Improves Prognostic Accuracy of GRACE 
(Global Registry of Acute Coronary Events) 
2.0 Risk Score in Patients With Acute 
Coronary Syndromes
Roland Klingenberg , MD; Soheila Aghlmandi , PhD; Lorenz Räber , MD, PhD; Alexander Akhmedov , PhD; 
Baris Gencer, MD; David Carballo , MD; David Nanchen , MD; Heiner C. Bucher , MD, MPH;  
Nicolas Rodondi , MD, MAS; François Mach , MD; Stephan Windecker , MD; Ulf Landmesser, MD; 
Arnold von Eckardstein , MD; Christian W. Hamm, MD; Thomas F. Lüscher , MD; Christian M. Matter, MD
BACKGROUND: It remains unclear whether the novel biomarker cysteine- rich angiogenic inducer 61 (CCN1) adds incremental 
prognostic value to the GRACE 2.0 (Global Registry of Acute Coronary Events) risk score and biomarkers high- sensitivity 
Troponin T, hsCRP (high- sensitivity C- reactive protein), and NT- proBNP (N- terminal pro- B- type natriuretic peptide) in patients 
with acute coronary syndromes.
METHODS AND RESULTS: Patients referred for coronary angiography with a primary diagnosis of acute coronary syndromes 
were enrolled in the Special Program University Medicine – Acute Coronary Syndromes and Inflammation cohort. The primary/
secondary end points were 30- day/1- year all- cause mortality and the composite of all- cause mortality or myocardial infarc-
tion as used in the GRACE risk score. Associations between biomarkers and outcome were assessed using log- transformed 
biomarker values and the GRACE risk score (versions 1.0 and 2.0). The incremental value of CCN1 beyond a reference model 
was assessed using Harrell’s C- statistics calculated from a Cox proportional- hazard model. The P value of the C- statistics 
was derived from a likelihood ratio test. Among 2168 patients recruited, 1732 could be analyzed. CCN1 was the strongest 
single predictor of all- cause mortality at 30 days (hazard ratio [HR], 1.77 [1.31, 2.40]) and 1 year (HR, 1.81 [1.47, 2.22]). Adding 
CCN1 alone to the GRACE 2.0 risk score improved C- statistics for prognostic accuracy of all- cause mortality at 30 days (0.87– 
0.88) and 1 year (0.81– 0.82) and when combined with high- sensitivity Troponin T, hsCRP, NT- proBNP for 30 days (0.87– 0.91), 
and for 1- year follow- up (0.81– 0.84). CCN1 also increased the prognostic value for the composite of all- cause mortality or 
myocardial infarction.
CONCLUSIONS: CCN1 predicts adverse outcomes in patients with acute coronary syndromes adding incremental information 
to the GRACE risk score, suggesting distinct underlying molecular mechanisms.
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Cardiovascular disease is the major cause of death, with one fifth of all cases attributable to coronary artery disease.1 Acute coronary syn-
dromes (ACS) constitute the acute manifestation of 
coronary artery disease caused by plaque rupture or 
erosion.2 Risk stratification remains of great impor-
tance because 1 of 6 patients experiences an adverse 
cardiovascular event within 1  year after an ACS de-
spite percutaneous coronary intervention and optimal 
medical treatment.3
Current guidelines recommend biomarkers com-
prising Troponin T (TnT) measured by high sensitive 
assays and NT- proBNP (N- terminal pro- B- type natri-
uretic peptide) along with clinical scores (ie, GRACE 
[Global Registry of Acute Coronary Events] risk score) 
for assessment of risk for adverse cardiovascular 
events in patients with ACS.4– 7 CRP (C- reactive pro-
tein) may further improve risk stratification; however, 
to a lesser extent.5 We recently demonstrated that the 
prognostic accuracy of the GRACE score (version 1.0) 
for major adverse outcomes is improved when com-
bining it with the biomarkers high- sensitivity Troponin 
T (hsTnT), hsCRP (high- sensitivity C- reactive protein), 
and NT- proBNP.8 The updated version 2.0 of the 
GRACE risk score uses nonlinear functions enabling 
better short- and long- term risk discrimination with re-
sults expressed as percentage risks, thus facilitating 
clinical use.9
Cysteine- rich angiogenic inducer 61 (CCN1 by offi-
cial unified nomenclature10) is a secreted matricellular 
protein with a variety of functions in angiogenesis, in-
flammation, and wound healing.11– 15 We have recently 
identified CCN1 as a novel biomarker of myocardial 
injury with increased levels measured in patients with 
ST- segment– elevation myocardial infarction (STEMI) 
and non– ST- segment– elevation myocardial infarction 
(NSTEMI) compared with patients with stable coronary 
artery disease.3 We considered the 95th percentile 
(589.01  ng/L) in patients with stable coronary artery 
disease as a clinically relevant cut- off.3 However, it 
remained unclear whether CCN1 adds further infor-
mation to risk stratification of patients with ACS when 
combining conventional cardiovascular biomarkers 
hsTnT, hsCRP, and NT- proBNP with the GRACE 2.0 
risk score.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Patients
Patients were enrolled in the Special Program University 
Medicine – Acute Coronary Syndromes and Inflammation 
(SPUM- ACS, ClinicalTrials.gov Identifier: NCT01000701) 
biomarker cohort 1 between December 2009 and 
October 2012 if they had a primary diagnosis of an ACS 
and were referred for coronary angiography to 1 of 4 uni-
versity hospitals in Switzerland.8 All patients had signed a 
written consent form, and the study was conducted with 
permission from the local ethical committees in accord-
ance with the Declaration of Helsinki. Blood was drawn 
from the inguinal arterial sheath at coronary angiography 
before percutaneous coronary intervention. Clinical and 
demographic parameters along with data on coronary 
anatomy and procedural aspects were ascertained and 
entered into an electronic database.
Biomarkers
Concentrations of CCN1 in serum were measured 
in stored duplicates of single serum aliquots using 
a semi- automated solid phase enzyme- linked im-
munosorbent assay (EIA- 5108, DRG Instruments 
GmbH, Marburg, Germany). The inter- and intra- 
assay coefficients of variation of CCN1 in SPUM- 
ACS patients were 3.21% and 3.46%, respectively. 
hsTnT and NT- proBNP were measured in serum ali-
quots on a Cobas e 602 reader, hsCRP on a Cobas c 
CLINICAL PERSPECTIVE
What Is New?
• Circulating biomarker cysteine- rich angiogenic 
inducer 61 adds independent information to 
risk stratification in patients with acute coronary 
syndrome beyond Global Registry of Acute 
Coronary Events risk score, high- sensitivity 
Troponin T, high- sensitivity C- reactive protein, 
and NT- proBNP (N- terminal pro- B- type natriu-
retic peptide).
What Are the Clinical Implications?
• Present data support further exploration of 
matricellular protein cysteine- rich angiogenic 
inducer 61 as a novel biomarker reflecting a dis-
tinct pathobiology in acute coronary syndromes.
Nonstandard Abbreviations and Acronyms
CCN1 CCN family member 1, syn. Cyr61, 
cysteine- rich angiogenic inducer 61
GRACE Global Registry of Acute Coronary 
Events
hsTnT high- sensitivity Troponin T
SPUM- ACS Special Program University 
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501 autoanalyzer (all Roche Diagnostics, Mannheim, 
Germany) with assay characteristics as reported by 
the manufacturer.
Clinical Risk Score Calculation
GRACE 1.0
The GRACE 1.0 score was used to calculate both in- 
hospital and long- term predictions of mortality and 
to assess the degree of disease severity in patients 
included in the current study. The GRACE 1.0 param-
eters used to assess the score for in- hospital mor-
tality comprised age, initial heart rate, systolic blood 
pressure, serum creatinine, Killip class, cardiac arrest 
on admission, elevated cardiac markers (conventional 
troponins as per local laboratories), and ST- segment 
deviation.16 The GRACE 1.0 parameters used to cal-
culate the score for long- term mortality comprised 
age, heart rate, systolic blood pressure, initial serum 
creatinine, history of congestive heart failure, his-
tory of myocardial infarction (MI), elevated cardiac 
markers (conventional troponins as per local labora-
tories), ST- segment depression, and no in- hospital 
percutaneous coronary intervention.17 The GRACE 
1.0 scores were calculated using a program written 
in Stata statistical software (Version 13, Stata Corp, 
and College Station, TX), and we used the standard 
scoring of GRACE 1.0, as mentioned in the reference 
publications.16,17
GRACE 2.0
The original GRACE risk score (GRACE 1.0) used linear 
scores in combination with a nomogram to estimate 
the overall score. To improve prognostic accuracy, es-
pecially for 1- year risk periods, the updated GRACE 
2.0 score uses nonlinear functions for age, systolic 
blood pressure, serum creatinine, and congestive 
heart failure.9 The GRACE 2.0 scores were calculated 
using a program implemented in R Core Team (2019) 
(A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, 
Austria, https://www.R- proje ct.org/). The code is im-
plemented based on GRACE ACS risk score 2.0 cal-
culator documentation.
Outcomes
The primary end point was all- cause mortality within 
30- day and 1- year follow- up. The secondary end point 
was the composite of all- cause mortality or recurrent 
MI, both end points as defined in the GRACE risk score. 
Additional outcomes comprising repeat revasculariza-
tion, cerebrovascular events (transient ischemic attack 
or stroke), and stent thrombosis were also assessed.8 
All events were adjudicated by 3 independent senior 
cardiologists using prespecified forms.
Statistical Analysis
This study aimed to assess the performance of CCN1 
in combination with GRACE risk scores (GRACE 1.0 
and GRACE 2.0), hsTnT, NT- proBNP, and hsCRP in 
predicting clinical outcomes. Clinical characteristics 
were presented as means with SDs and P values from 
t tests for continuous variables. Categorical variables 
were shown as counts with percentages and P val-
ues from χ2 or Fisher exact tests. Time- to- first event or 
composite events were analyzed throughout, censor-
ing patients at 30- day or 1- year, or last valid contact 
date. For the development of the prediction model(s) 
we followed 7 steps proposed by Steyerberg.18 These 
steps comprise (1) consideration of the research ques-
tion and initial data inspection, (2) coding of the pre-
dictors, (3) model specification, (4) model estimation, 
(5) evaluation of model performance, (6) internal valida-
tion, and (7) model presentation.
We used Cox proportional- hazards models to eval-
uate possible associations between the outcomes all- 
cause mortality and all- cause mortality or recurrent MI 
(at 30- day and 1- year follow- up) and log- transformed 
GRACE 2.0 risk scores, biomarkers (CCN1, hsTnT, NT- 
proBNP, and hsCRP), and continuous GRACE 1.0 risk 
scores. We report unadjusted hazard ratios (HRs) be-
cause potential confounders are part of the GRACE 
scores. The added predictive ability of a new predic-
tor combined with an existing model was assessed by 
Harrell’s C- statistics calculated from a Cox regression 
model and Integrated Discrimination Improvement 
index, which is based on a logistic model.19 The P value 
of the C- statistics derived from a likelihood ratio test 
comparing the Cox proportional- hazards model(s) with 
and without the new marker(s). The internal validation 
of the models is done using bootstrapping methods 
with 100 replications with samples of 1732 patients.
Two- sided P values were reported throughout, and 
P values <0.05 were considered statistically significant. 
Statistical analyses were performed using Stata statis-
tical software (Version 16.1, Stata Corp, and College 
Station, TX). The forest plots are produced using the 
“forestplot” function from the “rmeta” package of the R 
3.6.1 R (Foundation for Statistical Computing, Vienna, 
Austria; https://www.R- proje ct.org/.)
RESULTS
Among 2168 patients with ACS enrolled, 1732 
(79.9%) had available biomarker measurements. 
Complete follow- up data were available in 99.1% of 
the analyzed patients at 30- day, and 95.7% of pa-
tients at 1- year follow- up (Figure  1). Baseline char-
acteristics showed a predominance of NSTEMI 
(43.1%) and STEMI (52.9%) entities, respectively. 
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144.17±32.97 (in- hospital) and 123.20±26.18 (long- 
term), and GRACE 2.0 risk scores were 6.39±8.6% 
(in- hospital) and 13.01±13.42% (Table 1). A compari-
son between patients with and without biomarker 
analyses revealed no differences in baseline char-
acteristics except for periprocedural medications 
(Table  S1). Adherence to discharge medications 
was good (96.5% at 1 year from 99.2% at discharge 
for aspirin and 93.5% at 1  year from 98.1% at dis-
charge for statins; Table S2). The primary end point 
all- cause death occurred in 32 cases (1.8%), and the 
secondary end point (composite of all- cause death 
or MI) occurred in 58 cases (3.3%) (Table S3).
CCN1 Provides Independent Information 
to Predict Adverse Outcomes
Following univariable Cox models showing significant 
associations for the GRACE risk score (version 1.0 
and 2.0) and individual biomarkers (CCN1, hsTnT, NT- 
proBNP, and hsCRP) (Table S4), multivariable Cox mod-
els for GRACE risk score, CCN1, hsTnT, NT- proBNP, and 
Figure 1. Flow diagram.
The flow diagram shows patient enrollment and follow- up throughout the study. T1 signifies blood drawn 
performed at coronary angiography. ACS indicates acute coronary syndromes; CCN1, cysteine- rich 
angiogenic inducer 61; hsCRP, high- sensitivity C- reactive protein; hsTnT, high- sensitivity Troponin T; and 
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hsCRP for 30- day and 1- year follow- up were performed 
in 1732 patients. Unlike any of the other biomarkers, 
CCN1 was independently associated with all- cause 
mortality and the composite of all- cause mortality or MI 
both short- and long- term, respectively (Figure 2). The 
result of bootstrapping for the multivariable Cox model 
was consistent with the actual model (Table S5).
CCN1 Provides Incremental Prognostic 
Accuracy Beyond Current Risk 
Stratification
In the comparative analysis (c- statistic) of individual bio-
markers (CCN1, hsTnT, NT- proBNP, and hsCRP) and 
combinations thereof against the GRACE risk score 
(version 1.0 and 2.0) as the reference model, CCN1 
consistently improved prognostic accuracy beyond the 
GRACE risk score to predict all- cause mortality and 
the composite of all- cause mortality or MI both short-
 and long- term, respectively (Table 2). These data for 
CCN1 were corroborated when integrated discrimina-
tion improvement index analysis was used (Table  3). 
Albeit statistically significant, the improvement of model 
performance in GRACE 1.0 risk score based on the 
Integrated Discrimination Improvement analysis was 
small for CCN1, especially with respect to predictions 
of 30- day all cause- mortality and slightly better for 1- 
year all- cause mortality. A similar increment in prognos-
tic accuracy for both end points and time intervals using 
both methods (c- statistics and Integrated Discrimination 
Improvement) was found for hsTnT, NT- proBNP, and 
hsCRP. The best prognostic accuracy (up to c- statistic 
0.91) was obtained when combining all 3 biomarkers 
with the GRACE risk score with the highest increment 
observed to predict all- cause mortality both short- and 
long- term, respectively (Table 2). In a subgroup analy-
sis, unlike in patients with NSTEMI, CCN1 did not add 
information to improve predictions of all- cause mortality 
in patients with STEMI (Table S6 through S9).
Dichotomized Analysis Based on Cut- off 
Demonstrates Worse Survival for Patients 
With Elevated CCN1 Levels
Using the previously identified cut- off from patients 
with stable coronary artery disease, we describe the 
baseline characteristics including biomarker levels and 
outcomes for patients with ACS with low versus high 
CCN1 levels (Table S10 and Figure S1).
DISCUSSION
We here report for the first time that the novel bio-
marker CCN1 provides independent incremental prog-
nostic information in patients with ACS for all- cause 
mortality beyond the clinical GRACE 2.0 risk score.
Table 1. Baseline Characteristics of Patients With ACS 
(n=1732)
Parameters n=1732 Analyzed
Age, y n=1732, 63.82±12.27
Sex, female n=1732, 367 (21.2%)
Body weight, kg n=1713, 80.33±15.20
Body mass index, kg/m² n=1711, 27.16±4.35
Medical history
Diabetes mellitus n=1732, 313 (18.1%)
Hypertension n=1732, 1018 (58.8%)
Hypercholesterolemia n=1732, 1072 (61.9%)
Current smoker n=1701, 674 (39.6%)
Family history of CAD n=1711, 432 (25.2%)
Chronic kidney disease* n=1728, 220 (12.7%)
History of stroke or TIA n=1732, 64 (3.7%)
Previous myocardial infarction n=1730, 266 (15.4%)
Previous PCls n=1731, 307 (17.7%)
Previous CABG n=1732, 101 (5.8%)
Clinical presentation
Unstable angina n=1732, 69 (4.0%)
NSTEMI n=1732, 747 (43.1%)
STEMI n=1732, 916 (52.9%)
Index procedure
PCI n=1732, 1564 (90.3%)
Any drug- eluting stent n=1633, 1229 (75.3%)
Any bare- metal stent n=1633, 292 (17.9%)
PTCA alone n=1633, 186 (11.4%)
CABG n=1633, 65 (4.0%)
Periprocedural medications
Unfractionated heparin n=1729, 1656 (95.8%)
LMWH n=1732, 82 (4.7%)
Bivalirudin n=1732, 78 (4.5%)
Glycoprotein IIb/IIIa antagonists n=1732, 445 (25.7%)
GRACE risk score
GRACE 1.0
In- hospital n=1732, 144.17±32.97
Long- term n=1732, 123.20±26.18
GRACE 2.0†
In- hospital death (%) n=1732, 6.39±8.60
In- hospital death/MI (%) n=1732, 18.26±8.70
1- y death (%) n=1732, 13.01±13.42
1- y death/MI (%) n=1732, 18.29±13.03
Depicted are counts (%) or means±SDs. ACS indicates acute coronary 
syndromes; CABG, coronary artery bypass graft; CAD, coronary artery 
disease; GRACE, Global Registry of Acute Coronary Events; LMWH, low- 
molecular weight heparin; MI, myocardial infarction; NSTEMI, non– ST- 
segment– elevation myocardial infarction; PCIs, percutaneous coronary 
interventions; PTCA, percutaneous transluminal coronary angioplasty; 
STEMI, ST- segment– elevation myocardial infarction; and TIA, transient 
ischemic attack.
*Based on creatinine- estimated glomerular filtration rate clearance of 
<60  mL/min per 1.73 m², using the Modification of Diet in Renal Disease 
(MDRD) formula.
†GRACE 2.0 returns percentage probability of observing a respective 
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Specifically, serum levels of CCN1 were inde-
pendently associated with all- cause mortality occur-
ring during 30- day and 1- year follow- up, respectively. 
Furthermore, CCN1 had independent prognostic 
accuracy in predicting the composite of all- cause mor-
tality or MI, both during short- and long- term follow- up. 
Indeed, the novel serum biomarker CCN1 turned out 
to be a reliable biomarker to predict all- cause mortality 
Figure 2. Forrest plot illustration of the relative prognostic accuracy of GRACE risk scores (version 1.0 in blue color and 2.0 
in red color) and biomarkers for short- term (A and B) and long- term (C and D) adverse outcomes (n=1732).
For GRACE 2.0 scores, and the biomarkers, natural logarithm was used, and hazard ratios were reported per 1 log- unit increase. CCN1 
indicates cysteine- rich angiogenic inducer 61; GRACE, Global Registry of Acute Coronary Events; hsCRP, high- sensitivity C- reactive 
protein; hsTnT, high- sensitivity Troponin T; MI, myocardial infarction; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
Table 2. Accuracy of Risk Prediction for All- Cause Mortality and All- Cause Mortality/MI (n=1732)
30- D All- Cause Mortality
GRACE 1.0* GRACE 2.0†
C- Statistic P Value C- Statistic P Value
In- hospital GRACE 0.867 … 0.868 …
GRACE+CCN1 0.876 0.001 0.876 0.002
GRACE+hsTnT 0.877 <0.001 0.886 <0.001
GRACE+NT- proBNP 0.875 0.007 0.876 0.002
GRACE+hsCRP 0.875 0.092 0.866 0.036
GRACE+CCN1+hsTnT 0.886 <0.001 0.895 <0.001
GRACE+CCN1+hsTnT+NT- proBNP 0.897 <0.001 0.905 <0.001
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.898 <0.001 0.906 <0.001
30- d all- cause mortality/MI
In- hospital GRACE 0.715 … 0.666 …
GRACE+CCN1 0.716 0.003 0.667 0.001
GRACE+hsTnT 0.717 0.046 0.667 0.011
GRACE+NT- proBNP 0.725 0.017 0.695 <0.001
GRACE+hsCRP 0.726 0.030 0.676 0.002
GRACE+CCN1+hsTnT 0.718 0.001 0.676 <0.001
GRACE+CCN1+hsTnT+NT- proBNP 0.727 <0.001 0.716 <0.001
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.738 <0.001 0.726 <0.001
1- y all- cause mortality
Long- term GRACE 0.765 … 0.805 …
GRACE+CCN1 0.795 <0.001 0.816 0.012
GRACE+hsTnT 0.786 0.001 0.806 0.004
GRACE+NT- proBNP 0.797 <0.001 0.827 <0.001
GRACE+hsCRP 0.787 <0.001 0.816 <0.001
GRACE+CCN1+hsTnT 0.806 <0.001 0.807 <0.001
GRACE+CCN1+hsTnT+NT- proBNP 0.827 <0.001 0.836 <0.001
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.838 <0.001 0.838 <0.001
1- y all- cause mortality/MI
Long- term GRACE 0.676 … 0.686 …
GRACE+CCN1 0.696 <0.001 0.685 0.045
GRACE+hsTnT 0.675 0.051 0.676 0.093
GRACE+NT- proBNP 0.697 <0.001 0.706 <0.001
GRACE+hsCRP 0.695 <0.001 0.707 <0.001
GRACE+CCN1+hsTnT 0.699 <0.001 0.676 0.027
GRACE+CCN1+hsTnT+NT- proBNP 0.726 <0.001 0.716 <0.001
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.736 <0.001 0.728 <0.001
CCN1 indicates cysteine- rich angiogenic inducer 61; GRACE, Global Registry of Acute Coronary Events; hsCRP, high- sensitivity C- reactive protein; hsTnT, 
high- sensitivity Troponin T; MI, myocardial infarction; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*We used continuous GRACE 1.0 risk scores. P values were based on likelihood ratio tests.
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and the composite of all- cause mortality or MI during 
the first year after an ACS when compared with hs- 
TnT, NT- proBNP, and hs- CRP. CCN1 retains its high 
prognostic accuracy irrespective of which version of 
the GRACE risk score is used (GRACE 1.0 or GRACE 
2.0), adding independent information.
In a post hoc subgroup analysis, CCN1 retained its 
incremental value in predicting adverse outcomes in pa-
tients with NSTEMI, unlike in patients with STEMI. In light 
of the rather low event rate in the entire cohort, a subgroup 
analysis is prone to a type I error. Thus, the observed fail-
ure of CCN1 to predict all- cause mortality (n=39) and the 
composite of all- cause mortality and/or MI (n=62) in the 
first 12 months after STEMI (n=916 patients) is likely at-
tributable to the low event rate rather than reflecting a true 
biological difference. The lack of a high event rate is a 
limitation that calls for a larger validation study to provide 
a clear answer to whether there is a difference between 
the NSTEMI and STEMI subgroups. From a clinical point 
of view, patients with NSTEMI constitute the entity among 
Table 3. IDI for All- Cause Mortality and All- Cause Mortality/MI (n=1732)
30- D All- Cause Mortality
GRACE 1.0* GRACE2.0†
IDI Value P Value IDI Value P Value
In- hospital GRACE risk score Reference … Reference …
GRACE+CCN1 0.030 0.049 0.021 0.055
GRACE+hsTnT 0.036 <0.001 0.039 0.004
GRACE+NT- proBNP 0.017 0.062 0.024 0.044
GRACE+hsCRP 0.006 0.259 0.011 0.184
GRACE+CCN1+hsTnT 0.035 0.089 0.028 0.086
GRACE+CCN1+hsTnT+NT- proBNP 0.037 0.062 0.029 0.073
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.036 0.070 0.030 0.082
30- d all- cause mortality/MI
In- hospital GRACE risk score Reference … Reference …
GRACE+CCN1 0.015 0.024 0.015 0.026
GRACE+hsTnT 0.009 <0.001 0.010 <0.001
GRACE+NT- proBNP 0.008 0.027 0.019 0.001
GRACE+hsCRP 0.006 0.102 0.011 0.010
GRACE+CCN1+hsTnT 0.017 0.025 0.018 0.032
GRACE+CCN1+hsTnT+NT- proBNP 0.019 0.012 0.018 0.018
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.022 0.009 0.021 0.012
1- y all- cause mortality
Long- term GRACE risk score Reference … Reference …
GRACE+CCN1 0.034 0.002 0.011 0.024
GRACE+hsTnT 0.014 0.004 0.015 <0.001
GRACE+NT- proBNP 0.028 <0.001 0.022 0.008
GRACE+hsCRP 0.017 0.006 0.015 0.024
GRACE+CCN1+hsTnT 0.036 0.001 0.013 0.019
GRACE+CCN1+hsTnT+NT- proBNP 0.038 <0.001 0.019 0.010
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.043 <0.001 0.022 0.007
1- y all- cause mortality/MI
Long- term GRACE risk score Reference … Reference …
GRACE+CCN1 0.017 0.001 0.005 0.025
GRACE+hsTnT 0.005 0.004 0.005 <0.001
GRACE+NT- proBNP 0.020 <0.001 0.019 <0.001
GRACE+hsCRP 0.018 <0.001 0.017 <0.001
GRACE+CCN1+hsTnT 0.018 <0.001 0.006 0.017
GRACE+CCN1+hsTnT+NT- proBNP 0.020 <0.001 0.011 0.006
GRACE+CCN1+hsTnT+NT- proBNP+hsCRP 0.025 <0.001 0.014 0.002
CCN1 indicates cysteine- rich angiogenic inducer 61; GRACE, Global Registry of Acute Coronary Events; hsCRP, high- sensitivity C- reactive protein; hsTnT, 
high- sensitivity Troponin T; IDI, Integrated Discrimination Improvement; MI, myocardial infarction; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
*We used continuous GRACE 1.0 risk scores. P values were based on likelihood ratio tests.
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patients with ACS with the greatest heterogeneity, and 
thus, a new biomarker reflecting specific pathophysiology 
with prognostic impact appears highly desirable. Two re-
cent studies in patients with NSTEMI managed with early 
revascularization showed that NT- proBNP was better in 
predicting adverse long- term outcomes than Troponin 
I and T measured with high- sensitive assays,20,21 cor-
roborating our data obtained in the SPUM- ACS cohort 
with the vast majority of patients receiving percutaneous 
coronary intervention (90.3%). Prior studies also reported 
improved risk stratification in patients with NSTEMI when 
adding NT- proBNP to clinical scores (Thrombolysis in 
Myocardial Infarction or GRACE, respectively) in a mul-
timarker approach.22,23 Our current data show that 
combining CCN1 with the GRACE risk score and cardio-
vascular biomarkers (hsTnT, hsCRP, and NT- proBNP) fur-
ther improved prognostic accuracy, albeit improvements 
were small in magnitude. Of note, when analyzed against 
the updated version 2.0 of the GRACE risk score as a 
reference, CCN1 remained a good predictor of risk; how-
ever, it was smaller in magnitude.
Our data show that CCN1 unmasks a distinct patho-
physiology translating into adverse outcome, which is 
currently not reflected by the established biomarkers 
hsTnT, hsCRP, and NT- proBNP. In our SPUM- ACS co-
hort, the incremental prognostic accuracy of CCN1 when 
added to the GRACE risk score is moderate from a clin-
ical standpoint. This may be attributable to the high rate 
of patients who were planned for an early invasive strat-
egy (rate of percutaneous coronary intervention: 90.3%). 
It would be interesting to learn whether CCN1 may in-
form the clinician on optimal patient management before 
treatment decisions are made using a separate valida-
tion cohort. Indeed, the role of the GRACE risk score in 
risk stratification of patients with ACS has recently been 
challenged by a neutral study outcome in the AGRIS 
(Australian GRACE Risk Score Intervention Study) in the 
design of a cluster randomized trial.24 In this trial, receipt 
of early invasive treatment was higher in the randomized 
arm where the GRACE risk score was calculated com-
pared with the standard care arm, unlike the combina-
tion of 3 individual outcomes (early invasive treatment, 
discharge prescription of 4 of 5 guideline- recommended 
pharmacotherapies, and cardiac rehabilitation referral) 
defined as the primary end point, which was not differ-
ent. Of note, death or MI were not different at 12 months 
between the 2 arms. However, interpretation of this trial 
is hampered by the fact that it was stopped prematurely 
before reaching the planned sample size because of 
slow recruitment with futility to detect a difference be-
tween groups based on an interim analysis.25
Our data warrant external validation in separate co-
horts to better assess the potential value of CCN1 in 
a clinical routine setting. In our study, most deaths for 
30- day mortality were cardiac in origin (29/32); however, 
for 1- year mortality, a different pattern emerges (57/72). 
Future work needs to clarify the role of CCN1 as a po-
tential marker for the prediction of recurrent cardiovas-
cular events as opposed to it being rather an unspecific 
marker of increased risk of death. We demonstrate that 
CCN1 is a novel independent prognostic factor: in other 
words a marker of risk. However, at this stage we do not 
aim to postulate that CCN1 is a risk factor where an in-
cremental stepwise increase in concentration translates 
into a change in outcome as has been demonstrated 
(ie, for hsTnT). CCN1 is a matricellular protein expressed 
in response to ischemic injury3 and is involved in wound 
healing and myocardial fibrosis.11– 15 Future research di-
rected at the role of CCN1 as a potential causal event in 
the sequelae of MI appears highly promising in order to 
define its value as a novel therapeutic target.
Limitations
The SPUM- ACS cohort comprises well- characterized 
patients with ACS with independently adjudicated 
follow- up throughout 1- year follow- up. The current 
analysis provides biomarker measurements at the time 
of coronary angiography. Temporal increases of NT- 
proBNP and hsCRP were found to be associated with 
adverse outcomes.26 We cannot provide biomarker 
kinetics of CCN1 as part of the current SPUM- ACS 
study. However, in light of the acute release kinetics of 
CCN1 in patients with ACS with peak levels obtained 
in the first 6 hours,3 it appears unlikely that analyses 
at additional time points would affect the prognostic 
impact of CCN1 taken just before percutaneous coro-
nary intervention. Because these data are derived from 
1 study, cross- validation in other cohorts is needed to 
assess the added value of CCN1 in risk prediction of 
patients with NSTEMI and STEMI, respectively.
CONCLUSIONS
Serum levels of CCN1 predict adverse outcomes in 
patients with ACS and provide independent added 
value to current risk stratification tools.
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Parameters n = 1732 analyzed n = 436 without biomarkers p-value 
Age (years) n = 1732,  63.82 ± 12.27 n = 436,  63.41 ± 13.10 0.545 
Sex (female) n = 1732,   367 (21.2%) n = 436,   96 (22.0%) 0.695 
Body weight (kg) n = 1713,  80.33 ± 15.20 n = 426,  80.21 ± 14.82 0.885 
  Body Mass Index (kg/m²) n = 1711,  27.16 ±  4.35 n = 426,  27.00 ±  4.30 0.476 
Medical history    
  Diabetes mellitus n = 1732,   313 (18.1%) n = 436,   83 (19.0%) 0.628 
  Hypertension n = 1732, 1018 (58.8%) n = 436,  250 (57.3%) 0.587 
  Hypercholesterolemia n = 1732, 1072 (61.9%) n = 434,  276 (63.6%) 0.543 
  Current smoker n = 1701,   674 (39.6%) n = 432,  187 (43.3%) 0.170 
  Family history of CAD n = 1711,   432 (25.2%) n = 415,  115 (27.7%) 0.317 
  Chronic kidney disease * n = 1728,   220 (12.7%) n = 434,   54 (12.4%) 0.936 
  History of stroke or TIA n = 1732,    64 (3.7%) n = 436,   18  (4.1%) 0.674 
  Previous myocardial infarction n = 1730,   266 (15.4%) n = 436,   60 (13.8%) 0.454 
  Previous PCls n = 1731,   307 (17.7%) n = 436,   74 (17.0%) 0.778 
  Previous CABG n = 1732,   101 (5.8%) n = 436,   21  (4.8%) 0.485 
Clinical presentation    
  Unstable angina n = 1732,     69 (4.0%) n = 436,  25  (5.7%) 0.115 
  NSTEMI n = 1732,   747 (43.1%) n = 436,  183 (42.0%) 0.705 
  STEMI n = 1732,   916 (52.9%) n = 436,  228 (52.3%) 0.830 
Index procedure    
  PCI n = 1732, 1564 (90.3%) n = 401,  371 (92.5%) 0.684 
    Any drug-eluting stent n = 1633, 1229 (75.3%) n = 401,  293 (73.1%) 0.369 
    Any bare-metal stent n = 1633,   292 (17.9%) n = 401,   84 (20.9%) 0.172 
    PTCA alone n = 1633,   186 (11.4%) n = 401,   39  (9.7%) 0.375 
  CABG n = 1633,    65 (4.0%) n = 401,   13  (3.2%) 0.563 
Peri-procedural medications    
  Unfractionated heparin n = 1729, 1656 (95.8%) n = 435,  415 (95.4%) 0.693 
  LMWH n = 1732,   82 (4.7%) n = 435,   34  (7.8%) 0.017 
  Bivalirudin n = 1732,   78 (4.5%) n = 435,   18  (4.1%) 0.796 
  Glycoprotein IIb/IIIa antagonists n = 1732,   445 (25.7%) n = 435,  140 (32.2%) 0.008 
GRACE risk score    
   GRACE 1.0     
      In-hospital n = 1732, 144.17 ± 32.97 n = 436, 143.97 ± 34.63 0.908 
      Long-term  n = 1732, 123.20 ± 26.18 n = 436, 122.85 ± 27.33 0.803 
   GRACE 2.0 +   - 
       In-hospital death (%) n = 1732,     6.39 ± 8.60 - - 
       In-hospital death/MI (%) n = 1732,   18.26 ± 8.70 - - 
       1-year death (%) n = 1732,   13.01 ± 13.42 - - 
       1-year death/MI (%) n = 1732,   18.29 ± 13.03 - - 
   Depicted are counts (%) or means ± SDs. 
   *Based on creatinine-estimated glomerular filtration rate clearance of <60 mL/min/1.73m²,    
   using the Modification of Diet in Renal Disease (MDRD) formula.    
   CABG, coronary artery bypass graft; CAD, coronary artery disease; LMWH, low-   
   molecular weight heparin; PCI, percutaneous coronary interventions; TIA, transient ischemic attack. 
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Table S2. Discharge and Medication (n=1732). 
 Count (%); sample size 
At Discharge  
   Aspirin  1693 (99.2%), n = 1706 
   Clopidogrel    796 (46.7%), n = 1706 
   Prasugrel    685 (40.2%), n = 1706 
   Any DAPT  1578 (92.5%), n = 1706 
   Statin  1673 (98.1%), n = 1705 
   ACE inhibitor  1307 (76.7%), n = 1705 
   Betablocker  1359 (79.8%), n = 1704 
   PPI    486 (28.5%), n = 1706 
   NSAID       26  (1.5%), n = 1706 
   Immunosuppressives       38  (2.2%), n = 1706 
At 30 days  
   Aspirin  1645 (98.1%), n = 1677 
   Clopidogrel    795 (47.4%), n = 1676 
   Prasugrel    651 (38.8%), n = 1676 
   Any DAPT 1517 (90.5%), n = 1677 
   Statin 1622 (96.7%), n = 1677 
   ACE inhibitor 1187 (70.8%), n = 1676 
   Betablocker  1399 (83.5%), n = 1676 
   PPI    460 (27.4%), n = 1677 
   NSAID       23  (1.4%), n = 1677 
   Immunosuppressives      31  (1.8%), n = 1677 
At 1 year  
   Aspirin  1534 (96.5%), n = 1590 
   Clopidogrel     678 (42.6%), n = 1590 
   Prasugrel     584 (36.7%), n = 1590 
   Any DAPT 1315 (82.7%), n = 1590 
   Statin 1484 (93.5%), n = 1588 
   ACE inhibitor     922 (58.1%), n = 1588 
   Betablocker  1245 (78.4%), n = 1588 
   PPI     441 (27.8%), n = 1588 
   NSAID        36  (2.3%), n = 1588 
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Table S3. Clinical outcomes (n=1732). 
Parameters n = 1732 
At 30 days  
     Death  32 (1.8%) 
        Cardiac death 29 (1.7%) 
     Myocardial infarction  27 (1.6%) 
     Revascularization (any)  35 (2.0%) 
     Revascularization (clinically indicated) 32 (1.8%) 
        Cerebrovascular events (Stroke and TIA)  14 (0.8%) 
           Stroke (any)  12 (0.7%) 
           CVE (Ischemic stroke)  11 (0.6%) 
           CVE (Intracerebral hemorrhage)    0 (0.0%) 
           CVE (Unclear etiology)   1 (0.1%) 
       TIA    2 (0.1%) 
     Stent thrombosis (definite)  15 (0.9%) 
     All-cause death or MI  58 (3.3%) 
At 1 year  
     Death    72 (4.2%) 
       Cardiac death    57 (3.3%) 
     Myocardial infarction    64 (3.7%) 
     Revascularization  111 (6.4%) 
     Revascularization (clinically indicated)  104 (6.0%) 
     Cerebrovascular events (Stroke and TIA)    32 (1.8%) 
        Stroke (any)    26 (1.5%) 
           CVE (Ischemic stroke)    23 (1.3%) 
           CVE (Intracerebral hemorrhage)      2 (0.1%) 
           CVE (Unclear etiology)      1 (0.1%) 
        TIA      7 (0.4%) 
     Stent thrombosis (definite)    19 (1.1%) 
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Table S4. Univariable Cox models for GRACE risk score (version 1.0 and 2.0), CCN1, 
hsTnT, NT-proBNP, and, hsCRP for 30-days and 1-year follow-up to predict all-cause 
mortality and all-cause mortality/myocardial infarction (n=1732). 
 
30-day all-cause mortality 
Hazard ratio p-value 
  
   In-hospital GRACE risk score 1.01  1.30 (1.20, 1.40) <0.001 
   In-hospital GRACE risk score 2.02 4.24 (3.02, 5.95) <0.001 
   CCN1 (ng/l) 2.63 (2.05, 3.38) <0.001 
   hsTnT (µg/l) 1.91 (1.49, 2.44) <0.001 
   NT-proBNP (ng/l) 1.83 (1.47, 2.28) <0.001 
   hsCRP (mg/l) 1.44 (1.16, 1.78) <0.001 
30-day all-cause mortality/MI   
   In-hospital GRACE risk score 1.01 1.20 (1.20, 1.30) <0.001 
   In-hospital GRACE risk score 2.02 4.26 (2.42, 7.49) <0.001 
   CCN1 (ng/l) 1.95 (1.56, 2.43) <0.001 
   hsTnT (µg/l) 1.29 (1.10, 1.52) 0.002 
   NT-proBNP (ng/l) 1.43 (1.23, 1.68) <0.001 
   hsCRP (mg/l) 1.31 (1.12, 1.54)  0.001 
1-year all-cause mortality   
   Long-term GRACE risk score 1.01 1.40 (1.30, 1.50) <0.001 
   1-year GRACE risk score 2.02 4.29 (3.22, 5.71) <0.001 
   CCN1 (ng/l) 1.98 (1.61, 2.43) <0.001 
   hsTnT (µg/l) 1.42 (1.22, 1.65) <0.001 
   NT-proBNP (ng/l) 1.86 (1.60, 2.15) <0.001 
   hsCRP (mg/l) 1.50 (1.30, 1.73) <0.001 
1-year all-cause mortality/MI   
   Long-term GRACE risk score 1.01 1.30 (1.20, 1.30) <0.001 
   1-year GRACE risk score 2.02 3.48 (2.65, 4.57) <0.001 
   CCN1 (ng/l) 1.57 (1.32, 1.87) <0.001 
   hsTnT (µg/l) 1.18 (1.06, 1.31) 0.002 
   NT-proBNP (ng/l) 1.53 (1.37, 1.70) <0.001 
   hsCRP (mg/l) 1.38 (1.24, 1.54) <0.001 
  1 We used continuous GRACE 1.0 scores, and HRs were reported per 10 score unit increase.  
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Table S5. Results of the multivariable Cox models using bootstrapping for GRACE risk 
score (version 1.0 and 2.0), CCN1, hsTnT, NT-proBNP, and, hsCRP for 30-days and 1-




30 days all-cause mortality 
GRACE 1.01 GRACE 2.02 
Hazard ratio p-value Hazard ratio p-value 
   In-hospital GRACE  1.20 (1.10, 1.30) <0.001 2.59 (1.70, 3.95) <0.001 
   CCN1 (ng/l) 1.77 (1.23, 2.55) 0.002 1.67 (1.11, 2.52) 0.014 
   hsTnT (µg/l) 1.46 (1.09, 1.95) 0.010 1.47 (1.11, 1.95) 0.008 
   NT-proBNP (ng/l) 1.11 (0.88, 1.41) 0.377 1.15 (0.90, 1.46) 0.264 
   hsCRP (mg/l) 1.05 (0.75, 1.48) 0.761 1.05 (0.76, 1.46) 0.767 
30 days all-cause mortality/MI     
   In-hospital GRACE  1.10 (1.00, 1.02) <0.001 1.92 (0.95, 3.86) 0.067 
   CCN1 (ng/l) 1.65 (1.26, 2.15) <0.001 1.73 (1.32, 2.27) <0.001 
   hsTnT (µg/l) 1.04 (0.84, 1.30) 0.712 1.02 (0.83, 1.27) 0.834 
   NT-proBNP (ng/l) 1.14 (0.96, 1.36) 0.133 1.24 (1.06, 1.46) 0.009 
   hsCRP (mg/l) 1.16 (0.95, 1.43) 0.146 1.17 (0.96, 1.44) 0.122 
1-year all-cause mortality     
   Long-term GRACE  1.20 (1.10, 1.30) <0.001 2.51 (1.74, 3.64) <0.001 
   CCN1 (ng/l) 1.81 (1.41, 2.31) <0.001 1.51 (1.13, 2.03) 0.006 
   hsTnT (µg/l) 1.03 (0.86, 1.25) 0.731 1.04 (0.86, 1.25) 0.685 
   NT-proBNP (ng/l) 1.25 (1.02, 1.54) 0.030 1.25 (1.03, 1.51) 0.021 
   hsCRP (mg/l) 1.23 (1.03, 1.48) 0.025 1.17 (0.98, 1.41) 0.088 
1-year all-cause mortality/MI     
   Long-term GRACE  1.10 (1.10, 1.20) <0.001 1.98 (1.40, 2.80) <0.001 
   CCN1 (ng/l) 1.58 (1.31, 1.91) <0.001 1.43 (1.16, 1.76) <0.001 
   hsTnT (µg/l) 0.92 (0.81, 1.05) 0.209 0.92 (0.80, 1.04) 0.183 
   NT-proBNP (ng/l) 1.24 (1.07, 1.43) 0.004 1.26 (1.10, 1.44) <0.001 
   hsCRP (mg/l) 1.26 (1.11, 1.43) <0.001 1.23 (1.08, 1.40) 0.002 
1 We used continuous GRACE 1.0 scores, and HRs were reported per 10 score unit increase.  
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Table S6. Subgroup analysis NSTEMI: Accuracy of risk prediction for all-cause 
mortality (n= 816). 
 
30-day all-cause mortality 
GRACE 1.01 GRACE 2.02 
C-statistic p-value C-statistic p-value 
   In-hospital GRACE  0.881  0.885  
   GRACE + CCN1 0.902 <0.001 0.918 <0.001 
   GRACE + hsTnT 0.892 0.022 0.909 0.007 
   GRACE + NT-proBNP 0.888 0.589 0.893 0.707 
   GRACE + hsCRP 0.884 0.033 0.887 0.0432 
   GRACE + CCN1 + hsTnT 0.904 <0.001 0.917 <0.001 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.904 <0.001 0.917 <0.001 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.903 <0.001 0.914 <0.001 
1-year all-cause mortality     
   Long-term GRACE  0.798  0.826  
   GRACE + CCN1 0.845 <0.001 0.847 0.0002 
   GRACE + hsTnT 0.807 0.148 0.826 0.118 
   GRACE + NT-proBNP 0.802 0.018 0.829 0.128 
   GRACE + hsCRP 0.799 0.360 0.827 0.686 
   GRACE + CCN1 + hsTnT 0.843 <0.001 0.843 <0.001 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.849 <0.001 0.847 <0.001 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.849 <0.001 0.848 <0.001 
1 We used continuous GRACE 1.0  scores. 
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Table S7. Subgroup analysis NSTEMI: Integrated discrimination index (IDI) for all-
cause mortality (n=816). 
 
30-day all-cause mortality 
GRACE 1.01 GRACE 2.02 
IDI value p-value IDI value p-value 
    
   In-hospital GRACE risk score Reference - Reference - 
   GRACE + CCN1 0.160 0.106 0.160 0.089 
   GRACE + hsTnT 0.021 0.011 0.029 0.026 
   GRACE + NT-proBNP 0.001 0.135 0.002 0.376 
   GRACE + hsCRP 0.021 0.264 0.020 0.379 
   GRACE + CCN1 + hsTnT 0.168 0.108 0.167 0.113 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.160 0.073 0.168 0.075 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.122 0.132 0.131 0.118 
1-year all-cause mortality     
   Long-term GRACE risk score Reference - Reference - 
   GRACE + CCN1 0.067 0.027 0.050 0.053 
   GRACE + hsTnT 0.006 0.286 0.013 0.032 
   GRACE + NT-proBNP 0.023 0.035 0.009 0.283 
   GRACE + hsCRP 0.003 0.374 0.001 0.664 
   GRACE + CCN1 + hsTnT 0.065 0.026 0.048 0.067 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.070 0.014 0.058 0.028 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.069 0.014 0.057 0.031 
1 We used continuous GRACE 1.0 scores. 
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Table S8. Subgroup analysis STEMI: Accuracy of risk prediction for  all-cause 
mortality (n=916). 
 
30-day all-cause mortality 
GRACE 1.01 GRACE2.02 
C-statistic p-value  C-statistic p-value 
   In-hospital GRACE risk score 0.853 - 0.854 - 
   GRACE + CCN1 0.853 0.250 0.858 0.310 
   GRACE + hsTnT 0.869 <0.001 0.869 <0.001 
   GRACE + NT-proBNP 0.897 <0.001 0.894 <0.001 
   GRACE + hsCRP 0.889 <0.001 0.894 <0.001 
   GRACE + CCN1 + hsTnT 0.872 0.002 0.873 0.003 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.897 <0.001 0.893 0.001 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.905 <0.001 0.906 <0.001 
1-year all-cause mortality     
   Long-term GRACE risk score 0.755 - 0.805  
   GRACE + CCN1 0.762 0.028 0.803 0.292 
   GRACE + hsTnT 0.772 0.002 0.809 0.015 
   GRACE + NT-proBNP 0.810 <0.001 0.830 0.002 
   GRACE + hsCRP 0.794 <0.001 0.837 <0.001 
   GRACE + CCN1 + hsTnT 0.781 <0.001 0.807 0.025 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.820 <0.001 0.828 0.007 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.828 <0.001 0.842 0.002 
1 We used continuous GRACE 1.0  scores. 
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Table S9. Subgroup analysis STEMI: Integrated discrimination index (IDI) for all-cause 
mortality (n=916). 
 
30-day all-cause mortality 
GRACE 1.01 GRACE 2.02 
IDI value p-value IDI value p-value 
   In-hospital GRACE risk score Reference - Reference - 
   GRACE + CCN1 0.005 0.322 0.005 0.336 
   GRACE + hsTnT 0.043 0.004 0.043 0.010 
   GRACE + NT-proBNP 0.039 0.038 0.040 0.061 
   GRACE + hsCRP 0.035 0.071 0.040 0.121 
   GRACE + CCN1 + hsTnT 0.006 0.373 0.006 0.386 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.009 0.279 0.008 0.356 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.016 0.159 0.014 0.240 
1-year all-cause mortality     
   Long-term GRACE risk score Reference - Reference - 
   GRACE + CCN1 0.015 0.014 0.006 0.094 
   GRACE + hsTnT 0.022 0.001 0.018 0.008 
   GRACE + NT-proBNP 0.037 <0.001 0.026 0.029 
   GRACE + hsCRP 0.040 0.002 0.030 0.044 
   GRACE + CCN1 + hsTnT 0.017 0.016 0.008 0.086 
   GRACE + CCN1 + hsTnT + NT-proBNP 0.016 0.035 0.009 0.096 
   GRACE + CCN1 + hsTnT + NT-proBNP + hsCRP 0.025 0.018 0.015 0.056 
1 We used continuous GRACE 1.0 scores. 
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Table S10. Baseline characteristics for different categories of CCN1. 
 
Parameters 
Total CCN1≤589.01 ng/l CCN1>589.01 ng/l 
N = 1732 N = 1039 N = 693 
Age  n = 1732,  63.82  ± 12.27 n = 1039,  63.15  ± 12.00 n = 693,  64.82 ± 12.60 
Sex (female) n = 1732,   367 (21.2%) n = 1039,  192 (18.5%) n = 693,  175 (25.3%) 
Weight n = 1713, 80.33 8 ±15.20 n = 1035,  81.79  ± 15.42 n = 678,  78.09 ± 14.58 
   BMI n = 1711,  27.16  ±  4.35 n = 1034,  27.58  ±  4.43 n = 677,  26.53 ±  4.14 
Diabetes mellitus (yes) n = 1732,   313 (18.1%) n = 1039,  204 (19.6%) n = 693,  109 (15.7%) 
Hypertension (yes) n = 1732,  1018 (58.8%) n = 1039,  633 (60.9%) n = 693,  385 (55.6%) 
Hypercholesterolemia  n = 1732,  1072 (61.9%) n = 1039,  667 (64.2%) n = 693,  405 (58.4%) 
Current smoker (yes) n = 1701,   674 (39.6%) n = 1018,  419 (41.2%) n = 683,  255 (37.3%) 
Family history of CAD n = 1711,   432 (25.2%) n = 1031,  270 (26.2%) n = 680,  162 (23.8%) 
Renal failure (yes (<60 
eGFR)) 
n = 1728,   220 (12.7%) n = 1036,  110 (10.6%) n = 692,  110 (15.9%) 
History of stroke or TIA (yes) n = 1732,    64  (3.7%) n = 1039,   38  (3.7%) n = 693,   26  (3.8%) 
Previous MI (yes) n = 1730,   266 (15.4%) n = 1039,  186 (17.9%) n = 691,   80 (11.6%) 
Previous PCls (yes) n = 1731,   307 (17.7%) n = 1039,  217 (20.9%) n = 692,   90 (13.0%) 
Previous CABG (yes) n = 1732,   101  (5.8%) n = 1039,   66  (6.4%) n = 693,   35  (5.1%) 
Acute coronary syndrome n = 1732 n = 1039 n = 693 
    unstable angina  69  (4.0%) 62  (6.0%) 7  (1.0%) 
    non-ST-elevation MI  747 (43.1%) 604 (58.1%) 143 (20.6%) 
    ST-elevation MI  916 (52.9%) 373 (35.9%) 543 (78.4%) 
Congestive heart failure n = 1721 n = 1034 n = 687 
    Killip I 1481 (86.1%) 928 (89.7%) 553 (80.5%) 
    Killip II 168  (9.8%) 86  (8.3%) 82 (11.9%) 
    Killip III 32  (1.9%) 16  (1.5%) 16  (2.3%) 
    Killip IV 40  (2.3%) 4  (0.4%) 36  (5.2%) 
Systolic blood pressure n = 1723, 130.52 ±23.42 n = 1035, 131.94 ± 22.54 n = 688, 128.39 ± 24.54 
Heart rate n = 1725,  75.96 ± 15.78 n = 1035,  75.08 ± 15.32 n = 690,  77.27 ± 16.38 
Intervention performed (Yes) n = 1732,  1564 (90.3%) n = 1039,  916 (88.2%) n = 693,  648 (93.5%) 
Intervention - any PCI 
stenting (yes) 
n = 1633,  1497 (91.7%) n =  963,  876 (91.0%) n = 670,  621 (92.7%) 
Any Drug-eluting stent (yes) n = 1633,  1229 (75.3%) n =  963,  742 (77.1%) n = 670,  487 (72.7%) 
Any Bare-metal stent (yes) n = 1633,   292 (17.9%) n =  963,  148 (15.4%) n = 670,  144 (21.5%) 
Intervention - any PCI 
balloon (yes) 
n = 1633,   186 (11.4%) n =  963,  120 (12.5%) n = 670,   66  (9.9%) 
Intervention - any CABG 
(yes) 
n = 1633,    65  (4.0%) n =  963,   46  (4.8%) n = 670,   19  (2.8%) 
Unfract. Heparin (yes) n = 1729,  1656 (95.8%) n = 1037,  992 (95.7%) n = 692,  664 (96.0%) 
LMWH (yes) n = 1732,    82  (4.7%) n = 1039,   58  (5.6%) n = 693,   24  (3.5%) 
Bivalirudin (yes) n = 1732,    78  (4.5%) n = 1039,   44  (4.2%) n = 693,   34  (4.9%) 
GP IIb/IIIa (yes) n = 1732,   445 (25.7%) n = 1039,  213 (20.5%) n = 693,  232 (33.5%) 
PPI (yes) n = 1721,   261 (15.2%) n = 1032,  162 (15.7%) n = 689,   99 (14.4%) 
GRACE risk scores    
    GRACE 1.0     
        In-hospital  n = 1732, 144.17 ± 32.97 n = 1039, 136.96 ± 29.69 n = 693, 154.99 ± 34.66 
        Long-term  n = 1732, 123.20 ± 26.18 n = 1039, 122.11 ± 25.93 n = 693, 124.85 ± 26.49 
    GRACE 2.0    
        In-hospital death (%) n = 1732,   6.39 ±  8.60 n = 1039,   4.48 ±  4.91 n = 693,   9.25 ± 11.63 
        In-hospital death/MI (%) n = 1732,  18.26 ±  8.70 n = 1039,  15.41 ±  6.60 n = 693,  22.53 ±  9.68 
        1-year death (%) n = 1732,  13.01 ± 13.42 n = 1039,  10.41 ±  9.69 n = 693,  16.92 ± 16.86 
        1-year death/MI (%) n = 1732,  18.29 ± 13.03 n = 1039,  15.57 ±  9.74 n = 693,  22.35 ± 15.97 
Concentration of biomarkers     
    Mean ± SD    
        CCN1 (ng/l) n = 1732, 992.06 ± 3803.91 n = 1039, 362.65 ± 113.41 n = 693, 1935.72 ± 5889.76 
        hsTnT (µg/l) n = 1732, 0.65 ± 1.29 n = 1039, 0.63 ± 1.14 n = 693, 0.67 ± 1.48 
        NT-proBNP (ng/l) n = 1732, 1507.42 ± 3834.9 n = 1039, 1379.80 ± 2883.91 n = 693, 1698.76 ± 4924.52 
        hsCRP (mg/L) n = 1732, 10.71 ± 24.16 n = 1039, 13.02 ± 27.50 n = 693, 7.24 ± 17.47 
    Median (IQR)    
        CCN1 (ng/l) n = 1732, 488.09  
            (334.81 to 866.78) 
n = 1039, 360.05  
           (279.11 to 443.06)  
n = 693, 1055.75  
          (751.61 to 1772.03) 
        hsTnT (µg/l) n = 1732, 0.20 (0.06 to 0.70) n = 1039, 0.22 (0.06 to 0.76) n = 693, 0.19 (0.06 to 0.60) 
        NT-proBNP (ng/l) n = 1732, 385.5 (124 to 1320) n = 1039, 450 (152 to 1409) n = 693, 270 (88 to 1163) 
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